Breaking down barriers: is intestinal mucus degradation by

Akkermansia muciniphila is a specialized mucin-degrading bacterium that plays a pivotal role in gut health and disease. This review examines the dualistic nature of A. muciniphila mucin degradation, exploring its potential benefits and risks. As a mucin specialist, A. muciniphila uses glycosyl hydrolases and mucinases to degrade mucins, producing metabolites like short-chain fatty acids (SCFAs), branched-chain fatty acids (BCFAs), succinate, and other compounds. These metabolites benefit host health and cross-feed other commensal microbes, such as butyrate producers. A. muciniphila levels are inversely correlated with several disease states, such as obesity, diabetes, and inflammatory states, and administration of A. muciniphila has been found by several groups to restore and maintain gut homeostasis. However, under certain conditions, such as low dietary fiber or conditions with an altered gut microbiota, excessive mucin degradation by A. muciniphila can compromise the mucus barrier, increasing susceptibility to inflammation, infection, and pathogenic overgrowth. Elevated A. muciniphila levels have been associated with various diseases and medications, including graft versus host disease (GVHD) and irradiation, and shown to exacerbate infections by enteric pathogens. The context-dependent effects of A. muciniphila and mucin degradation underscore the need for a nuanced understanding of its interactions with the host and microbial community. This review aims to provide a balanced perspective on the implications of gut microbial mucus degradation, highlighting that it can be good, and it can be bad depending on the context.